Zimmer Biomet Holdings, Inc. (ZBH) to Distribute Quarterly Dividend of $0.24 on July 31st

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced a quarterly dividend on Friday, May 22nd. Stockholders of record on Thursday, June 25th will be paid a dividend of 0.24 per share by the medical equipment provider on Friday, July 31st. This represents a c) dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th.

Zimmer Biomet has a payout ratio of 11.5% meaning its dividend is sufficiently covered by earnings. Analysts expect Zimmer Biomet to earn $8.91 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Trading Down 0.8%

NYSE ZBH opened at $87.29 on Tuesday. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The stock has a 50 day moving average of $87.13 and a 200-day moving average of $90.05. The company has a market cap of $16.89 billion, a PE ratio of 22.67, a PEG ratio of 2.59 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts anticipate that Zimmer Biomet will post 8.49 EPS for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.